


Stabilis



Butorphanol tartrate



Noms commerciaux

Dolorex	France
Torbugesic	France



Stabilité en mélange






































		0.08 mg/ml	25°C		Droperidol : 0.05 mg/ml	15		3378
		0.08 mg/ml	4°C		Droperidol : 0.05 mg/ml	15		3378
		0.08 mg/ml	25°C		Droperidol : 0.05 mg/ml	15		3378
		0.08 mg/ml	4°C		Droperidol : 0.05 mg/ml	15		3378
		0,067 mg/ml	25°C		Ketamine hydrochloride : 1,4 mg/ml Droperidol : 0,034 mg/ml	14		4115
		0.05 mg/ml	25°C		Ropivacain hydrochloride : 1 & 2 mg/ml	15		3780
		0,067 mg/ml	4°C		Ketamine hydrochloride : 1,4 mg/ml Droperidol : 0,034 mg/ml	14		4115
		0.05 mg/ml	4°C		Ropivacain hydrochloride : 1 & 2 mg/ml	15		3780



Compatibilités

	Butorphanol tartrate : 0.04 mg/ml Allopurinol sodium : 3 mg/ml		307
	Butorphanol tartrate : 0.04 mg/ml Amifostine : 10 mg/ml		3

		Butorphanol tartrate : 0.04 mg/ml Amifostine : 10 mg/ml		3
		Butorphanol tartrate : 0.04 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Butorphanol tartrate : 0.04 mg/ml Aztreonam : 40 mg/ml		99
		Butorphanol tartrate : 0.04 mg/ml Bivalirudin : 5 mg/ml		1713
		Butorphanol tartrate Calcium gluconate		3644
		Butorphanol tartrate : 0.04 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Butorphanol tartrate : 0.04 mg/ml Cladribine : 0.015 mg/ml		1496
		Butorphanol tartrate : 0.04 mg/ml Cladribine : 0.5 mg/ml		1496
		Butorphanol tartrate : 0.04 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Butorphanol tartrate : 0.04 mg/ml Docetaxel : 0.9 mg/ml		1754
		Butorphanol tartrate : 0.04 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Butorphanol tartrate : 0,08 mg/ml Droperidol : 0,05 mg/ml		3378
		Butorphanol tartrate : 0.4 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Butorphanol tartrate : 0,04 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Butorphanol tartrate : 0.04 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Butorphanol tartrate : 0.04 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Butorphanol tartrate : 0.04 mg/ml Filgrastim : 30 µg/ml		244
		Butorphanol tartrate : 0.04 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Butorphanol tartrate : 0.04 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Butorphanol tartrate : 0.08 mg/ml Granisetron hydrochloride : 0.03 & 0.06 mg/ml		3805
		Butorphanol tartrate : 0.04 mg/ml		1415
		Butorphanol tartrate Glycopyrronium bromide		3599
		Butorphanol tartrate : 0.04 mg/ml		301
		Butorphanol tartrate : 0.04 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Butorphanol tartrate : 0.04 mg/ml Hetastarch : 60 mg/ml		1721
		Butorphanol tartrate : 0.05 >> 0.15 mg/ml Ketamine hydrochloride : 1 >> 4 mg/ml		181
		Butorphanol tartrate : 0.04 mg/ml Labetalol hydrochloride : 1 mg/ml		386

		Butorphanol tartrate : 0.04 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Butorphanol tartrate : 0.04 mg/ml Linezolid : 2 mg/ml		1925
		Butorphanol tartrate Magnesium sulfate		3838
		Butorphanol tartrate : 0.04 mg/ml Melphalan : 0.1 mg/ml		169
		Butorphanol tartrate : 1 mg/ml Midazolam hydrochloride : 2.5 mg/ml		404
		Butorphanol tartrate : 0.4 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Butorphanol tartrate : 0,04 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Butorphanol tartrate : 0.04 mg/ml Paclitaxel : 1.2 mg/ml		248
		Butorphanol tartrate : 0.04 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Butorphanol tartrate : 0.04 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Butorphanol tartrate : 0.04 mg/ml Propofol : 10 mg/ml		300
		Butorphanol tartrate : 0.04 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Butorphanol tartrate : 0,05 mg/ml Ropivacain hydrochloride : 1 & 2 mg/ml		3780
		Butorphanol tartrate : 0.04 mg/ml Sargramostim : 10 µg/ml		335
		Butorphanol tartrate : 0.04 mg/ml Teniposide : 0.1 mg/ml		905
		Butorphanol tartrate : 0.04 mg/ml Thiotepa : 1 mg/ml		249
		Butorphanol tartrate : 0,08 mg/ml Tropisetron hydrochloride : 0,05 mg/ml		668
		Butorphanol tartrate : 0.04 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.





































59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
181	Revue	Fuchao Chen, Hui Xiong, Jinguo Yang, Baoxia Fang, Jun Zhu, Benhong Zhou. Butorphanol and Ketamine Combined in Infusion Solutions for Patient-Controlled Analgesia Administration: A Long-Term Stability Study. Med Sci Monit 2015 ; 21:1138-1145.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.

384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
668	Revue	Chen, Fu-Chao; Shi, Xiao-Ya; Li, Peng; Yang, Jin-Guo; Zhou, Ben-Hong. Stability of Butorphanol–Tropisetron Mixtures in 0.9% Sodium Chloride Injection for Patient-Controlled Analgesia Use. Medicine 2015 ; 94(6):e432.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.

1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3378	Revue	Chen F-C, Fang B-X, Li P, Yang J-G, Zhou B-H. Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection Am J Health-Syst Pharm 2013 ; 70:515-519.
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercy 2013
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3780	Revue	Chen F, Peng L, Zhou B, Fang B, Yang Y. Stability of an epidural analgesic admixture containing butorphanol tartrate and ropivacaine hydrochloride EJHP 2015 ;22:7-11
3805	Revue	Chen F.C, Xiong H, Liu H.M, Fang B.X, Li P. Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags. Am J Health-Syst Pharm 2015 ; 72:1374-1378.
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4115	Revue	Fang B, Wang L, Gu J, Chen F, Shi X. Physicochemical stability of ternary admixtures of butorphanol, ketamine, and droperidol in polyolefin bags for patient-controlled analgesia use. Drug Design Dev Ther 2016 ;10:3873-3878



Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité en mélange
 Contenant	 Solvant
 Concentration	 Température
 Conservation	 Molécule
 Durée de stabilité	 Bibliographie
 Verre	 Chlorure de sodium 0,9%
 A l'abri de la lumière	 Jour
 Polyvinyl chlorure	 Polyolefine
 Compatibilités	 Compatible
 Glucose 5%	 Perte de turbidité
 Incompatible	 Incompatibilité non précisée
 NaCl 0,9% + bactériostatique	 Nutrition parentérale (mélange ternaire)
 Nutrition parentérale (mélange binaire)	 Solvant spécifique
 Précipitation immédiate	 Aucun
 NaCl 0,9% ou glucose 5%	 Voie d'administration
 Intraveineuse	 Intramusculaire
 Bibliographie	 Dictionnaire